Medicare price talks defended by DoJ

Trump administration defends Medicare drug price talks in case brought by Novartis
The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate prescription drug prices, a sign that some consumer advocates said suggests the Trump administration is willing to maintain the controversial program.
Medicare price talks defended by DoJ as Trump pledges to lower drug prices
Responding to a lawsuit by Novartis (NVS), the U.S. Department of Justice has defended Medicare price negotiations, signaling that the controversial program introduced by former President Biden will continue under President Trump’s new administration.
5.3 Million Medicare Users to Benefit From New Drug Price Negotiations
The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic and Wegovy.
How Medicare Says It Arrives At ‘Fair’ Prescription Drug Prices
We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it selected for negotiation.
Could the Trump Administration Change the Medicare Drug Price Negotiation Program?
CMS recently issued a statement saying that it's continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be made and what changes they would like to see.
Trump’s DOJ Defends Drug Price Program in Third Circuit Brief
The Trump administration is moving forward with the defense of a Biden-era plan that allows Medicare to negotiate drug prices against Novartis AG’s appeal at the Third Circuit.
Mintz IRA Update — The Future of the Medicare Drug Price Negotiation Program
The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second round of negotiations as
Trump's High-Stakes Meeting with Big Pharma: A Game-Changer for Drug Pricing?
President Donald Trump will meet with major drugmakers' executives to discuss drug pricing and insurance changes. Key topics include Medicare price negotiations, pharmacy benefit management, and potential tariffs on pharmaceuticals.
Trump to Meet Pharma Leaders as They Seek Drug Policy Changes
The industry is also pushing for curbs on the rebates they pay pharmacy benefit managers, which act as middlemen between drug companies and consumers, in exchange for favorable pl
Mintz IRA Update — From the Desk of ML Strategies: The Medicare Drug Price Negotiation Program Under the Second Trump Administration
The start of Donald Trump’s second presidency and Republican control in the 119th Congress raises questions about the future of the IRA’s
Trump to Meet Pharma CEOs to Discuss Drug Pricing, Tariffs, and Medicare Negotiations
U.S. President Donald Trump is set to meet with top pharmaceutical executives on Thursday, a White House official confirmed. The discussions will focus on Medicare drug price negotiations, pharmacy benefit managers (PBMs),
NBC New York11d
Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
President Donald Trump likely won't do away with a process that allows Medicare to negotiate drug prices with manufacturers, even as he erases Joe Biden's other policy accomplishments. But Trump ...
Yahoo Finance10d
Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma
From the first 10 drugs already negotiated under ... pharma lobby have been fighting against the negotiation program — calling it a form of “price setting” — the operational focus has ...